Enter assignee name

Forward Citations = 0

Loading Chart...

2 inventors (with patents filed for the assignee):

Daniel L Alkon (6 out of 59 patents)

Thomas J Nelson (4 out of 54 patents)

6 patents: Sort by Forward Citations

1. 12016837 - Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases (2024-06-25),

2. 11826345 - Dosing regimens of PKC activators (2023-11-28),

3. 11820745 - PKC-activating compounds for the treatment of neurodegenerative diseases (2023-11-21),

4. 11390596 - PKC-activating compounds for the treatment of neurodegenerative diseases (2022-07-19),

5. 11273139 - Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases (2022-03-15),

6. 11045447 - Methods for inducing synaptogenesis with synaptic growth factor activating compounds (2021-06-29),

Synaptogenix, Inc. is a biopharmaceutical company focused on the development of novel therapies for neurodegenerative diseases. The company's lead drug candidate, Bryostatin-1, is being investigated for its potential to treat Alzheimer's disease and other cognitive disorders. Through its innovative research and strategic partnerships, Synaptogenix aims to improve the lives of patients suffering from debilitating neurological conditions.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

6 Patents

#1,027 in New York, NY

#2,693 in New York

#44,917 in US

New York, NY, United States of America

Synaptogenix, Inc.

Forward Citations = 0

2 inventors:

Daniel L Alkon (6 out of 59 patents)

Thomas J Nelson (4 out of 54 patents)

Please report any incorrect information to [email protected]